Stryker SYK Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| MedSurg and Neurotechnology: | $15.34B+1.0% | $15.19B+4.7% | $14.51B+3.4% | $14.03B+4.1% | $13.48B-0.3% | |
| Orthopaedics: | $9.93B0.0% | $9.92B+0.6% | $9.87B+0.9% | $9.79B+0.5% | $9.74B+7.3% | |
| Segment operating income by Business | ||||||
| MedSurg and Neurotechnology: | $4.4B-1.3% | $4.46B+5.8% | $4.22B+3.3% | $4.08B+4.2% | $3.91B-2.2% | |
| Orthopaedics | $3.03B-0.3% | $3.03B+1.9% | $2.98B+1.6% | $2.93B+1.5% | $2.88B+11.3% | |
| Reclassification to: cost of sales by Business | ||||||
| MedSurg and Neurotechnology: | $5.83B+2.0% | $5.71B+3.9% | $5.5B+2.1% | $5.38B+2.4% | $5.26B-1.2% | |
| Orthopaedics | $2.76B+1.8% | $2.72B+1.9% | $2.67B+2.3% | $2.61B+0.9% | $2.58B+7.7% | |
| Additions and adjustments by Business | ||||||
| MedSurg and Neurotechnology | $2.38B-27.3% | $3.28B+22.7% | $2.67B+29.4% | $2.06B+41.6% | $1.46B+71.1% | |
| Orthopaedics | -$750K+25.0% | -$1M-101% | $74.25M-50.3% | $149.5M-33.5% | $224.75M-25.1% | |
| Selling, general and administrative expenses by Business | ||||||
| MedSurg and Neurotechnology: | $3.92B+1.8% | $3.85B+4.1% | $3.7B+5.5% | $3.51B+6.3% | $3.3B+3.0% | |
| Orthopaedics | $3.17B-1.4% | $3.21B-1.4% | $3.25B-0.6% | $3.27B-0.4% | $3.29B+5.6% | |
| Research, development and engineering expenses by Business | ||||||
| MedSurg and Neurotechnology: | $954M+2.5% | $931M+4.5% | $891M+4.9% | $849M+6.5% | $797M+1.7% | |
| Orthopaedics | $530M-2.2% | $542M-1.6% | $551M-0.7% | $555M-1.6% | $564M+4.4% | |
| D&A by Business | ||||||
| MedSurg and Neurotechnology: | $235M+3.1% | $228M+14.0% | $200M-2.0% | $204M+1.0% | $202M-2.9% | |
| Orthopaedics | $444M+2.8% | $432M+0.5% | $430M-0.2% | $431M-0.2% | $432M-0.2% | |
| Foreign exchange and other by Business | ||||||
| MedSurg and Neurotechnology | $35.75M-51.0% | $73M-4.3% | $76.25M-4.1% | $79.5M-3.9% | $82.75M-3.8% | |
| Orthopaedics | $56.75M-36.2% | $89M+267% | $24.25M+160% | -$40.5M+61.5% | -$105.25M+38.1% | |
| Capital Expenditures During Period by Business | ||||||
| MedSurg and Neurotechnology: | $245M+11.4% | $220M-24.9% | $293M+1.7% | $288M+7.5% | $268M-2.9% | |
| Orthopaedics | $288M-2.7% | $296M+29.8% | $228M+3.6% | $220M+2.8% | $214M-7.0% | |
| Net Sales by Product | ||||||
| Endoscopy | $3.81B0.0% | $3.81B+3.8% | $3.67B+1.6% | $3.61B+3.8% | $3.48B+2.6% | |
| Hips | $1.88B+0.9% | $1.87B+2.0% | $1.83B+2.1% | $1.79B+2.2% | $1.75B+2.9% | |
| Instruments | $3.37B+2.5% | $3.29B+4.3% | $3.16B+2.6% | $3.08B+2.3% | $3.01B+6.0% | |
| Knees | $2.69B+1.2% | $2.66B+2.4% | $2.59B+2.3% | $2.54B+1.5% | $2.5B+2.1% | |
| Medical | $4.16B-1.0% | $4.2B+3.5% | $4.06B+1.2% | $4.02B+2.1% | $3.93B+2.1% | |
| Spine | $21M-88.6% | $185M-49.0% | $363M-31.4% | $529M-24.6% | $702M-0.7% | |
| Trauma and Extremities | $4.04B+2.3% | $3.95B+2.3% | $3.86B+3.0% | $3.75B+3.5% | $3.62B+3.3% | |
| Vascular | $2.08B+5.6% | $1.97B+11.2% | $1.77B+12.5% | $1.57B+12.2% | $1.4B+7.3% | |
| Net Sales by Geography | ||||||
| International | $6.23B+1.9% | $6.11B+2.8% | $5.94B+1.7% | $5.84B+1.6% | $5.75B+1.7% | |
| United States | $19.04B+0.2% | $19.01B+3.1% | $18.44B+2.6% | $17.98B+2.9% | $17.47B+3.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Stryker break its business down?
- Stryker (SYK) reports net sales by business across 2 parts — MedSurg and Neurotechnology: and Orthopaedics:. Each is extracted from the segment footnotes and tracked over time.
- Where does Stryker's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Stryker's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
